Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 408 across all filing types
Latest filing 2025-03-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an individual or entity acquires a significant stake (typically 5% or more) in a company. This document details the shareholding status, changes in holdings, and the purpose of the holding (e.g., influencing management). Based on the provided categories, this fits the 'Major Shareholding Notification' (MRQ) classification.
2025-03-05 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by a company (Abion) regarding the approval of a clinical trial plan amendment by the Korean Ministry of Food and Drug Safety (MFDS). It details the clinical trial phase, purpose, methodology, and regulatory status. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a standard regulatory disclosure of material business information, it is classified as a Regulatory Filing (RNS).
2025-02-14 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인신청)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by Abion Inc. regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically an application for a change in clinical trial approval for their drug candidate ABN401. This type of disclosure is a standard regulatory filing in the Korean market (KRX) used to inform investors of material developments in clinical trials. Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-02-14 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed with the Korea Exchange (KRX) regarding a 'Major Management Matter' (Investment Judgment), specifically the approval of a clinical trial plan amendment for a drug candidate (ABN401). This type of disclosure is a standard regulatory filing in the Korean market for material corporate events. Since it does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a Regulatory Filing (RNS).
2025-02-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) regarding a significant change in revenue or profit/loss structure (30% or more). This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to report preliminary financial results or significant fluctuations before the final audit report is finalized. Since it provides key financial highlights and reasons for the change, it functions as an Earnings Release (ER). FY 2024
2025-02-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual relationships (such as collateral agreements) of major shareholders and their special related parties. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-01-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.